Mechanisms of opioid tolerance and dependence;Mecanismes de la tolerance et de la dependance aux opioides

Annales Francaises d'Anesthesie et de Reanimation

Volumn 18, Issue 8, 1999, Pages 866-895

  Muller, A ^a,b   Koch, B ^b   Rene F ^b   Boutillier, A L ^b   See, V ^b   Loeffler, J P ^b  

^a HÔPITAL CIVIL   (France)

^b CNRS   (France)

Author keywords

Cellular mechanisms; Clinical variability; Opioids; Tolerance

Indexed keywords

OPIATE; OPIATE RECEPTOR; NARCOTIC AGENT;

ARTICLE; CHRONIC PAIN; DRUG DEPENDENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERANCE; HUMAN; MEDICAL INFORMATION; PRESCRIPTION; SIDE EFFECT; CHRONIC DISEASE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; NERVE CELL; OPIATE ADDICTION; PAIN; PATHOPHYSIOLOGY; REVIEW; SECOND MESSENGER;

CHRONIC DISEASE; DRUG TOLERANCE; GENE EXPRESSION REGULATION; HUMANS; NARCOTICS; NEURONS; OPIOID-RELATED DISORDERS; PAIN; RECEPTORS, OPIOID; SECOND MESSENGER SYSTEMS;

EID: 0033209277     PISSN: 07507658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0750-7658(00)88194-0     Document Type: Review

References (188)

1. Gourlay GK. Long-term use of opioids in chronic patients with nonterminal disease states. Pain Rev 1994; 1: 62-76.
2. Nestler EJ, Alreja M, Aghajanian GK. Molecular and cellular mechanisms of opiate action: Studies in the rat locus coeruleus. Brain Res Bull 1994; 35: 521-8.
3. Shimoyama N, Shimoyama M, Inturrisi CE, Elliot KJ. Ketamine attenuates and reverses morphine tolerance in rodents. Anesthesiology 1996; 85: 1357-66.
4. Manning BH, Mao J, Frenk H, Price DD, Mayer DJ. Continuous co-administration of dextromethorphan or MK-801 with morphine: Attenuation of morphine dependence and naloxone-revesible attenuation of morphine tolerance. Pain 1996; 67: 79-88.
5. Mao J, Price DD, Mayer DJ. Mechanisms of hyperalgesia and tolerance: A current view of their possible interactions. Pain 1995; 62: 259-74.
6. Colpaert FC. System theory of pain and of opiate analgesia: No tolerance to opiates. Pharm Rev 1996; 48: 355-411.
7. Vaccarino AL, Marek P, Kest B, Ben-Eliyahu S, Couret LC, Kao B, Morphine fails to produce tolerance when administered in the presence of formalin pain in rats. Brain Res 1993; 627: 287-90.
8. Mestek A, Chen Y, Hurley JH, Bye LS, Campbell AD, Liu J, The μ opioid receptor: Cellular function and tolerance development. Reg Peptides 1994; 54: 193-4.
9. Wuster M, Schultz R, Herz A. Opioid tolerance and dependence: Reevaluating the unitary hypothesis. TIPS 1985; 6: 64-7.
10. Dambisya YM, Lee TL. Role of nitric oxide in the induction and expression of morphine tolerance and dependence in mice. Br J Pharmacol 1996; 117: 914-8.
11. Aley KO, Levine JD. Different mechanisms mediate development and expression of tolerance and dependence for peripheral mu-opioid antinociception in rat. J Neurosci 1997; 17: 8018-23.
12. Schultz R, Wuster M, Krenss H, Herz A. Selective development of tolerance without dependence in multiple opiate receptors of mouse vas deferens. Nature (Lond) 1980; 285: 242-3.
13. Rezvani A, Hwang F, Song ZH, Lin ET, Way EL. Supersensitivity to electrical stimulation for assessing physical dependence on opioids in isolated tissues. J Pharmacol Exp Ther 1990; 254: 52-7.
14. Koob GF, Maldonado R, Stinus L. Neural substrates for opiate withdrawal. TINS 1992; 15: 186-91.
15. Aston-Jones G, Shipley MT, Chouvet G, Ennis M, VanBockstaele E, Pieribone V, Afferent regulation of locus coeruleus neurons: Anatomy, physiology, pharmacology. In: Barnes CD, Pompeiano O, eds. Progress in Brain Research, vol 88. Amsterdam: Elsevier; 1991. p. 47-75.
16. Luppi PH, Aston-Jones G, Akaoka H, Chouvet G, Jouvet M. Afferent projections to the rat locus coeruleus demonstrated by retrograde and anterograde tracing with cholera toxin B subunit and phaseolus vulgaris leucoagglutinin. Neuroscience 1995; 65: 119-60.
17. Proudfit HK, Clarck FM. The projections of locus coeruleus neurons to the spinal cord. In: Barnes CD, Pompeiano O, eds. Progress in Brain Research, vol 88. Amsterdam: Elsevier; 1991. p. 123-41.
18. Mansour A, Fox CA, Akil H, Watson SJ. Opioid-receptor mRNA expression in rat CNS: Anatomical and unctional implications. TINS 1995; 18: 22-9.
19. Elde R, Arvidsson H, Riedl M, Vulchanova I, Lee JH, Dado R, Distribution of neuropeptide receptors. New views of peptidergic neurotransmission made possible by antibodies to opioid receptors. Ann NY Acad Sci 1995; 757: 390-404.
20. Aston-Jones G, Hirata H, Akaoka H. Local opiate withdrawal in locus coeruleus in vivo. Brain Res 1997; 765: 331-6.
21. Javelle R, Renaud B, Lambas-Senas L. Monamine metabolism in the locus coeruleus measured concurrently with behavior during opiate withdrawal: An in vivo microdialysis study in freely moving rats. J Neurochem 1997; 68: 683-90.
22. Christie MJ, William JT, Osborne PB, Bellchambers CE. Where is the locus in opioid withdrawal? TINS 1997; 18: 134-40.
23. Rasmussen K. The role of locus coeruleus and N-methyl-D-aspartic acid (NMDA) and AMPA receptors in opiate withdrawal. Neuropsychopharmacology 1995; 13: 295-300.
24. Detweiler DJ, Rohde DS, Basbaum AI. The development of opioid tolerance in the formalin test in the rat. Pain 1995; 63: 251-4.
25. Cepeda MS, Carr D. Anesthésie locorégioanle et réponse au stress . In: Gauthier-Lafaye P, Muller A, eds. Anesthésie Locorégionale et Traitement de la Douleur. Paris: Masson; 1996. p. 53-73.
26. Vaccarino AL, Couret LC. Relationship between hypothalamic-pituitary-adrenal activity and blockade of tolerance to morphine analgesia by pain: A strain comparison. Pain 1995; 63: 385-9.
27. Dougherty PM, Pellis NR, Dafny N. The brain and the immune system: An intact immune system is essential for the manifestation of withdrawal in opiate addicted rats. Neuroscience 1990; 36: 285-9.
28. Collin E, POulain P, Gauvain-Piquard A, Petit G, Pichard-Leandri E. Is disease progression the major factor in morphine « tolerance » in cancer pain treatment? Pain 1993; 55: 319-26.
29. Muller A. Physiologie, neurochimie et plasticité des voies nociceptives. In: Gauthier-Lafaye P, Muller A, eds. Anesthésie Locorégionale et Traitement de la Douleur. Paris: Masson; 1996. p. 433-90.
30. Cabot PJ, Carter L, Gaiddon C, Zhang Q, Schäfer M, Loeffler JP, Immune cell-derived β-endorphin. Production, release, and control of inflammatory pain in rats. J Clin Invest 1997; 100: 142-8.
31. Stein C. Peripheral mechanisms of opioid analgesia. Anesth Analg 1993; 76: 182-91.
32. Stein C, Pfluger M, Yassouridis A, Hoelzl J, Lehrberger K, Weite C, No tolerance to peripheral morphine analgesia in presence of opioid receptor expression in inflamed synovia. J Clin Invest 1996; 98: 793-9.
33. Coderre TJ, Katz J, Vaccarino AL, Melzack R. Contribution of central neuroplasticity to pathological pain: Review of clinical and experimental evidence. Pain 1993; 52: 259-85.
34. Castro-Lopes JM, Tavares I, Tölle TR, Coito A, Coimbra A. Increase in GABAergic cells and GABA levels in the spinal cord in unilateral inflammation of the hindlimb in the rat. Eur J Neurosci 1992; 4: 296-301.
35. Calza L, Pozza M, Zanni M, Manzini CU, Manzini Ehökfelt T. Peptide plasticity in primary sensory neurons and spinal cord during adjuvant-induced arthritis in the rat: An immunocytochemical and in situ hybridization study. Neuroscience 1998; 82: 575-89.
36. Sluka KA, Dougherty PM, Sorkin LS, Willis WD, Westlund KN. Neural changes in acute arthritis in monkeys. III. Changes in substance P, calcitonin gene-related peptide and glutamate in the dorsal horn of the spinal cord. Brain Res Rev 1992; 17: 29-38.
37. Weihe E, Millan MJ, Höllt, Nohr D, Herz A Induction of the gene encoding prodynorphin by experimentally induced arthritis enhances staining for dynorphin in the spinal cord. Neuroscience 1989; 31: 77-95.
38. Igwe OJ, Ning L. Regulation of second-messenger systems in the rat spinal cord during prolonged peripheral inflammation. Pain 1994; 58: 63-75.
39. Maekawa K, MInami M, Masuda T, Satoh M. Expression of μ-and κ-, but not δ-, opioid receptor mRNAs is enhanced in the spinal horn of the arthritic rats. Pain 1995; 64 : 365-71.
40. Besse D, Weil-Fugazza J, Lombard MC, Butler SH, Besson JM. Monoarthritis induces complex changes in μ-, δ- and κ-opioid binding sites in the superficial dorsal horn of the rat spinal cord. Eur J Pharmacol 1992; 233: 123-31.
41. Stanfa LC, Sullivan AF, Dickenson AH. Alteration in neuronal excitability and the potency of spinal mu, delta and kappa opioids after carrageenan-induced inflammation. Pain 1992; 50: 345-54.
42. Pockett S. Spinal cord plasticity and chronic pain. Anesth Analg 1995; 80: 173-9.
43. Portenoy RK, Foley KM, Inturrisi C. The nature of opioid responsiveness and its implications for neuropathic pain: New hypotheses derived from studies of opioid infusions. Pain 1990; 43: 273-86.
44. Bennet GJ. Animal models of neuropathic pain. In: Gebhart GF, Hammond DL, Jensen TS, eds. Proceedings of The VIIth World Congress on Pain. Seattle: IASP Press; 1994. p. 495-510.
45. Luo L, Puke MJC, Wiesenfeld-Hallin Z. The effects of intrathecal morphine and clonidine on the prevention and reversal of spinal cord hyperexcitability following sciatic section in the rat. Pain 1994; 58: 245-52.
46. Yamamoto T, Mizuguchi T. The effects of oral morphine and buprenorphine on autotomy following brachial nerve sections in rat. Pain 1991; 75: 817-26.
47. Desmeules JA, Kayser V, Guilbaud G. Selective opioid receptor agonists modulate mechanical allodynia in an animal model of neuropathic pain. Pain 1993; 53: 277-85.
48. Yamamoto T, Shimoyama N, Asano H, Mizuguchi T. Time-dependent effect of morphine and time-independent effect of MK 801, an NMDA antagonist, on the thermal hyperesthesia induced by unilateral constriction injury to the sciatic nerve in the rat. Anesthesiology 1994; 80: 1311-9.
49. Nahin RL, Ken RL. Primary sensory neurons exhibit altered gene expression in a rat model of neuropathic pain. Pain 1994; 58: 95-108.
50. Seltzer R, Cohn S, Ginzburg R, Belin B. Modulation of neuropathic pain behavior in rats by spinal desinhibition and NMDA receptor blockade of injury discharge. Pain 1991; 45: 69-75.
51. EIsenberg E, Vos BP, Strassmann AM. The NMDA antagonist memantine blocks pain behavior in a rat model of formalin-induced facial pain. Pain 1993; 54: 301-7.
52. Mao J, Price D, Mayer DJ. Experimental mononeuropathy reduces the antinociceptive effects of morphine: Implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain. Pain 1995; 61: 353-64.
53. Dhawan BN, Cesselin F, Raghubir R, Resine T, Bradley PB, Portoghese PS, International union of pharmacology. XII. Classification of opioid receptors. Pharmacol Rev 1996; 48: 567-92.
54. Fujimoto JM, Arts KS. Spinal dynorphin A 1-17: Possible mediator of antianalgesic action. Neuropharmacology 1990; 26: 609-17.
55. Shukla VK, Lemaire S. Non opioid effects of dynorphins: Possible role of the NMDA receptor. TIPS 1994; 15: 420-4.
56. Pan ZZ. μ-opposing actions of the κ-opioid receptor. TIPS 1998; 94-8.
57. Miaskowski C, Sutlers KA. Antinociceptive and motor effects of delta/mu and kappa/mu combinations of intrathecal opioid agonists. Pain 1992; 49: 137-44.
58. Matthes HWD, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Loss of morphine induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioid receptor gene. Nature 1996; 383: 819-23.
59. Clarke WP, Bond RA. The elusive nature of intrinsic efficacy. TIPS 1998; 19: 270-6.
60. Pert CB, Snyder SH. Opiate receptor binding of agonists and antagonists affected differentially by sodium. Mol Pharmacol 1974; 10: 868-79.
61. Kissin I, Brown PT, Bradley EL. Magnitude of acute tolerance to opioids is not related to their potency. Anesthesiology 1991; 75: 813-6.
62. Duttarroy A, Yoburn BC. The effect of intrinsic efficacy on opioid tolerance. Anesthesiology 1995; 82: 1226-36.
63. Steven CW, Yaksh TL. Potency of infused spinal antinociceptive agents is inversely related to magnitude of tolerance after continuous infusion. J Pharm Exp Ther 1989; 250: 1-8.
64. Muller A. Analgésie par voie périmédullaire. In: Gauthier-Lafaye P, Muller A, eds. Anesthésie Locorégionale et Traitement de la Douleur. Paris: Masson; 1996. p. 491-553.
65. Christrupp LL. Morphine metabolites. Acta Anaest Scand 1997; 41: 116-22.
66. Smith DG, Smith MD. Morphine-3-glucuronide: Evidence to support its putative role in the development of tolerance to the antinociceptive effects of morphine in the rat. Pain 1995; 62: 51-60.
67. Nicholas AP, Hökfelt T, Pieribone VA. The distribution and significance of CNS adrenoceptors examined with in situ hybridization. TIPS 1996; 17: 245-54.
68. Goodschild CS, Guo Z, Davies A, Gent JP. Antinociceptive actions of intrathecal xylazine: Interactions with spinal cord opioid pathways. Br J Anaest 1996; 76: 544-51.
69. Guo TZ, Jiang JY, Buttermann AE, Maze M. Dexmedetomidine injection into the locus coeruleus produces antinociception. Anesthesiology 1996; 84: 873-81.
70. Stevens DW, Monasky MS, Yaksh TL. Spinal infusion of opiate and alpha-2-agonists in rats: Tolerance and cross-tolerance studies. J Pharm Exp Ther 1987; 244: 63-8.
71. Gurtu S, Shuka S, Mukerjee D. Morphine, clonidine coadministration in subanalgesic doses: Effective control of tonic pain. NeuroReport 1994; 58: 245-52.
72. Cesselin F. Opioid and anti-opioid peptides. Fund Clin Pharm 1995; 9: 409-33.
73. Becker C, Mauborgne A, Bourgoin S, Benoliel JJ. La cholecystokinine: Peptide « anti-opioïde »: Données biochimiques. In: Monographie ≪ Opioïdes et Antiopioïdes ≫. Société française de la douleur. Paris, 1997. p. 75-100.
74. Dourish CT, O'Neill MF, Coughlan J, Kitchener SJ, Hawley D, Iversen SD. The selective CCK-B receptor antagonist L 365. 260 enhances morphine analgesia and prevents morphine tolerance in the rat. Eur J Pharmacol 1990; 176: 35-44.
75. Jhamandas KH, MArsala M, Ibuki T, Yaksh TL. Spinal amino acid release and precipitated withdrawal in rats chronically infused with spinal morphine. J Neurosci 1996; 16: 2758-66.
76. Rasmussen K. Afferent effects on locus coeruleus in opiate withdrawal. In: Barnes CD, Pompeiano O, eds. Progress in Brain Research, vol. 88. Amsterdam: Elsevier; 1991. p. 207-16.
77. Rasmussen K, Kendrick WT, Kogan JH, Aghajanian GB. A selective AMPA antagonist, LY 293. 558, suppresses morphine withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal. Neuropsychopharmacology 1996; 15: 497-505.
78. Elliott K, Minami N, Kolesnikov YA, Pasternak GW, Inturrisi CE. The NMDA receptor antagonists, LY 274. 614 and MK-801, and the nitric oxide synthase inhibitor, NG-nitro-L-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa opioids. Pain 1994; 56: 69-75.
79. Wiesenfeld-Hallin Z. Combined opioid-NMDA antagonist therapies: What advantages do they offer for the control of pain syndromes? Drugs 1998; 55: 1-4.
80. Bilsky EJ, Inturrisi CE, Sadee W, Hruby VJ, Porreca F. Competitive and non-competitive NMDA antagonists block the development of antinociceptive tolerance to morphine, but not to the selective mu or delta opioids in mice. Pain 1996; 68: 229-37.
81. ++ channels during opioid tolerance and supersenstivity in rats. J Pharm Exp Ther 1995; 274: 1538-44.
82. Santillan R, Hurle MA, Armijo JA, De Los Mozos R, Florez J. Nimodipine-enhanced opiate analgesia in cancer patients requiring morphine: A double-blind, placebo-controlled study. Pain 1998; 76: 17-26.
83. Machelska H, Ziolowska B, Mika J, Przewlocka B, Przewlocki R. Chronic morphine increases biosynthesis of nitric oxide synthase in the rat spinal cord. Neuro Report 1997; 8: 2743-7.
84. Bhargava HN, Bian JT, Kumar S. Mechanism of attenuation of morphine antinociception by chronic treatment with L-arginine. J Pharm Exp Ther 1997; 281: 707-12.
85. Vaupel DB, Kimes AS, London ED. Further in vivo studies on attenuating morphine withdrawal: Isoform-selective nitric oxide synthase inhibitors differ in efficacy. Eur J Pharmacol 1997; 324: 11-20.
86. Herman BH, Vocci F, Bridge P. The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Neuropsychopharmacology 1995; 13: 269-93.
87. Hibert MF, Hoflack J, Trump-Kallmeyer S, Bruinvels A. Modèles tridimensionnels des récepteurs couplés aux protéines G. Med Sci 1993; 9: 31-40.
88. Milligan G. Mechanisms of multifunctional signalling by G protein linked receptors. TIPS 1996; 14: 219-41.
89. Mons N, Cooper DMF. Adenylate cyclases: Critical foci in neuronal signaling. TINS 1995; 18: 536-42.
90. Bayewitch ML, Avidor-Reiss T, Levy R, Pfeuffer T, Nevo I, Simonds WF, Differential modulation of adenyl cyclases I and II by various G beta subunits. J Biol Chem 1998; 273: 2273-6.
91. Guillemette G. Messagers intracellulaires produits par la phospholipase C. Med Sci 1989; 5: 570-4.
92. Erneux C, Vanweyenberg V, DeSmedt F, Communi D. Implication des phosphatidylinositols et de leurs produits d'hydrolyse dans la signalisation cellulaire. Med Sci 1995; 11: 240-6.
93. Wojcikiewicz RJH, Tobin AB, Nahorsky SR. Desensitization of cell signalling mediated by phosphoinositidase C. TIPS 1993; 14: 279-85.
94. Litosch I. G-protein βγ subunits antagonize protein kinase C-dependent phosphorylation and inhibition of phospholipase C-β1. Biochem J 1997; 326: 701-7.
95. Huang KP. The mechanism of protein kinase C activation. TINS 1989; 12: 425-32.
96. Bornancin F. Phosphorylation et régulation de la protéine kinase C. Med Sci 1998; 14: 322-5.
97. Axelrod J, Burch RM, Jelsema CL. Receptor mediated activation of phospholipase A2 via GTP-binding proteins: Arachidonic acid and its metabolites as second messengers. TINS 1988; 11: 117-23.
98. Karoor V, Shih M, Tholanikunnel B, Malbon CC. Regulating expression and function of G-protein-linked receptors. Prog Neurobiol 1996; 48: 555-68.
99. Selbie LA, Hill SJ. G protein-coupled receptor cross-talk: The fine tuning of multiple receptor-signalling pathway. TIPS 1998; 19: 87-93.
100. Hadcock JR, Malbon CC. Regulation of receptor expression by agonists: Transcriptional and post-transcriptional controls. TINS 1991; 14: 242-7.
101. Chuang TT, Iacovelli L, Sallese M, DeBlasi A. G protein-coupled receptors: Heterologous regulation of homologous desensitization and its implications. TIPS 1996; 17: 416-21.
102. Inglese J, Freddmann NJ, Koch WJ, Lefkowitz RJ. Structure and mechanism of G protein-coupled receptor kinases. J Biol Chem 1993; 268: 23735-8.
103. Ferguson SSG, Downey WE, Colapietro AM, Barak LS, Menard L, Caron MG. Role of β-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science 1996; 271: 363-5.
104. Drewett JG, Garbers DL. The family of guanyl cyclase receptors and their ligands. Endocrine Rev 1994; 15: 135-62.
105. Boxall AR, Lancaster B. Tyrosines kinases and synaptic transmission. Eur J Neurosci 1998; 10: 2-7.
106. Marshall JC. Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation. Cell 1995; 80: 179-85.
107. Cobb MH, Goldsmith EJ. How MAP kinases are regulated. J Biol Chem 1995; 270: 14843-6.
108. Harrison C, Smart D, Lambert DG. Stimulatory effects of opioids. Br J Anaesth 1998; 81: 20-8.
109. Prather PL, Loh HH, Law PY. Interaction of δ-opioid receptors with multiple G proteins: A non-relationship between agonist potency to inhibit adenyl cyclase and to activate G proteins. Mol Pharmacol 1994; 45: 997-1003.
110. Tsu RC, Chan JSC, Wong YH. Regulation of multiple effectors by the cloned δ-opioid receptor: Stimulation of phospholipase C and type II adenylcyclase. J Neurochem 1995; 64: 2700-7.
111. 2+ concentration in SH-SY5Y cells. Br J Anaesth 1996; 76: 461-3.
112. Laugwitz KL, Offermans S, Spicher K, Schultz G. μ and δ opioid receptors differentially couple to G protein subtypes in membranes of human neuroblastoma SH-SY5Y cells. Neuron 1993; 10: 233-42.
113. Jordan B, Devi LA. Molecular mechanisms of opioids receptor signal transduction. Br J Anaesth 1998; 81: 12-9.
114. Tatsumi H, Costa M, Schimerlick M, North RA. Potassium conductance increased by noradrenaline, opioids, somatostatine and G-proteins: Whole-cell recording from guinea pig submucous neurons. J Neurosci 1990; 10: 1675-82.
115. Noel F, Iourgenko V, Pouille Y, Hanoune J. Approches moléculaires de l'action des opiacés. Med Sci 1994; 10: 1116-26.
116. 2+ transients by a μ-opioid agonist in dorsal horn neurons. Neuro Report 1997; 8: 3061-5.
117. Chieng B, Christie MJ. Local opioid withdrawal in rat single periaqueductal gray neurons in vitro. J Neurosci 1996; 16: 7128-36.
118. Martin G, Nie Z, Siggins GR. Mu-opioid receptors modulate NMDA receptor-mediated responses in nucleus accumbens neurons. J Neurosci 1997; 17: 11-22.
119. Shiekhattar R, Aston-Jones G. Modulation of opioid responses in brain noradrenergic neurons by the cyclic AMP cascade: Changes with chronic morphine. Neuroscience 1993; 57: 879-85.
120. + channels in rat spinal cord. Mol Brain Res 1996; 40: 261-70.
121. Mackler SA, Eberwine JH. Cellular adaptation to opiates alters ion-channels mRNA levels. Proc Nath Acad Sci USA 1994; 91: 385-91.
122. 2+ channel blocker, on naloxone-increased glutamate levels in the locus coeruleus of opioid-dependent rats. Brain Res 1996; 722: 212-6.
123. Hall S, Milne B, Jhamandas K. Nitric oxide synthase inhibitors attenuate acute and chronic morphine withdrawal response in the rat locus coeruleus: An in vivo voltametric study. Brain Res 1996; 739: 182-91.
124. + channel. J Biol Chem 1994; 269: 7839-42.
125. Baraban SC, Lothman EW, Lee A, Guyenet PG. Kappa opioid receptor-mediated suppression of voltage-activated potassium current in a catecholaminergic neuronal cell line. J Pharmacol Exp Ther 1995; 273: 927-33.
126. Suri C, Fung BP, Tischer AS, Chikaraishi D. Catecholaminergic cell lines from the brain and adrenal glands of tyrosine hydroxylase-SV40 T antigen transgenic mice. J Neurosci 1993; 13: 1280-91.
127. Bouvier C, Avram D, Peterson VJ, Hettinger B, Soderstrom K, Murray TF, Catecholaminergic CATH. A cells express predominantly δ-opioid receptors. Eur J Pharmacol 1998; 348: 85-93.
128. René F, Muller A, Jover E, Kieffer B, Koch B, Loeffler JP. Melanocortin receptors and δ-opioid receptors mediate opposite signalling actions of POMC-derived peptides in CATH. A cells. Eur J Neurosci 1998; 10: 1885-94.
129. Wang JF, Shun XJ, Yang HF, Ren MF, Han JS. Suppression by D-Pen2, D-Pen5 enkephalin on cyclic AMP dependent protein kinase-induced, but not protein kinase C-induced increment of intracellular free calcium in NG 108-15 cells. Life Sci 1993; 52: 1519-25.
130. Milligan G. Agonist regulation of cellular G protein levels and distribution: Mechanisms and cellular implications. TINS 1993; 14: 413-8.
131. Rubino T, Parenti M, Patrini G, Massi P, Parolaro M. Morphine withdrawal syndrome and G protein expression: A study of time course in the rat central nervous system. Eur J Neurosci 1995; 7: 2334-40.
132. Wang L, Gintzler AR. Altered μ-opiate receptor-G protein signal transduction following chronic morphine exposure. J Neurochem 1997; 68: 248-54.
133. Crain SM, Shen KF. Modulatory effects of Gs-coupled excitatory opioid receptor functions on opioid analgesia, tolerance and dependence. Neurochem Res 1996; 21: 1347-51.
134. Selley DE, Nestler EJ, Breivogel CS, Childers SR. Opioid receptor-coupled G-proteins in rat locus coeruleus membranes: Decrease in activity after chronic morphine treatment. Brain Res 1997; 746: 10-18.
135. (35)Gtp γS binding in SH-SY5Y human neuroblastoma cells as a model for the study of opioid tolerance. Reg Peptides 1994; 54: 91-2.
136. Maldonado R, Valverde O, Garbay C, Roques BP. Protein kinases in the locus coeruleus and periaqueductal gray matter are involved in the expression of opiate withdrawal. Naunyn-Schmiedebergs Arch Pharm 1995; 352: 565-75.
137. Guitart X, Nestler EJ. Identification of morphine-and cyclic AMP-regulated phosphoproteins (MARPPs) in the locus coeruleus and other regions of rat brain: Regulation by acute and chronic morphine. J Neurosci 1989; 9: 4371-87.
138. Matus-Leibovitch N, Nevo I, Vogel Z. Differential disribution of synapsin IIa and IIb mRNAs in various brain structures and the effect of chronic morphine administration on the regional expression of these isoforms. Mol Brain Res 1997; 45: 301-16.
139. Avidorreiss T, Nevo I, Saya D, Bayewitch M, Vogel Z. Opiate-induced adenyl cyclase superactivation is isozyme-specific. J Biol Chem 1997; 272: 5040-7.
140. 2A cells stably expressing a cloned μ-opiate receptor: A specific cellular model to study acute and chronic effects of morphine. Mol Brain Res 1995; 30: 269-78.
141. Blake AD, Bot G, Freemann JC, Reisinet T. Differential opioid regulation of the mouse opioid receptor. J Biol Chem 1997; 272: 782-90.
142. Carter BD, Medzihradsky F. Receptor mechanisms of opioid tolerance in SH-SY5Y human neural cells. Neuropharmacology 1993; 43: 465-73.
143. Lou LG, Pei G. Modulation of protein kinase C and cAMP-dependent protein kinase by delta-opioid. Bioch Biophys Res Com 1997; 236: 626-9.
144. Chneiweiss H. Protéines phosphatases: L'autre plateau de la balance. Med Sci 1998; 14: 259-61.
145. 2+: A story with a complex past and a promising future. TIPS 1997; 18: 266-9.
146. Burton CK, Ho IK, Hoskins B. Evidence for involvement of cyclic GMP phosphodiesterase in morphine tolerance. J Pharm Exp Ther 1990; 252: 104-11.
147. Miyame T, Fukushima N, Misu Y, Veda H. δ-opioid receptor mediates phospholipase C activation via Gi in Xenopus oocytes. FEBS 1993; 333: 311-4.
148. + currents. Br J Pharmacol 1995; 116: 2655-60.
149. Mayer DJ, Mao J, Price DD. The development of morphine tolerance and dependence is associated with translocation of protein kinase C. Pain 1995; 61: 365-74.
150. Narita M, Ohsawa M, Mizoguchi H, Kamei J, Tseng LF. Pre-treatment with protein kinase activator phorbol 12, 13-dibutyrate attenuates the antinociception induced by mu- but not epsilon-opiod receptor agonist in the mouse. Neuroscience 1997; 76: 291-8.
151. Narita M, Mizoguchi H, Kampine JP, Tseng LF. Role of protein kinase C in desensitization of spinal delta opioid-mediated antinociception in the mouse. Br J Pharm 1996; 118: 1829-35.
152. Ventayol P, Busquets X, Garcia-Sevilla JA. Modulation of immunoreactive protein kinase C alpha and beta isoforms and G proteins by acute and chronic treatments with morphine and other opiate drugs in rat brain. Naunyn-Schmiedebergs Arch Pharm 1997; 355: 491-500.
153. Garcia-Sevilla JA, Ventayol P, Busquets Y, LaHarpe R, Walzer C, Guimon J. Regulation of immunolabelled mu-opioid receptors and protein kinase C alpha and zeta isoforms in the frontal cortex of human opiate addicts. Neurosci Let 1997; 226: 29-32.
154. Louie AK, Bass ES, Zhan J, Law PY, Loh HH. Attenuation of opioid receptor activity by phorbol esters in neuroblastoma x glioma NG 108-15 hybrid cells. J Pharm Exp Ther 1990; 253: 401-7.
155. Hayashi C, Ueda H, Fukushima N, Katayama T, Misu Y. Protein kinase C inhibitor potentiates the agonist-induced GT-Pase activity in COS cell membranes expressing delta-opioid receptor. Mol Brain Res 1995; 33: 347-50.
156. 1-phospholipase C activation in xenopus oocytes. J Neurosci 1995; 15: 7485-99.
157. Mestek A, Hurley JH, Bye LS, Campbell AD, Chen Y, Tian M, The human mu opioid receptor: Modulation of functional desensitization by calcium/calmodulin-dependent protein kinase and protein kinase C. J Neurosci 1995; 15: 2396-2406.
158. Gies EK, Peters DM, Gelb CR, Knag KK, Peterfreund RA. Regulation of mu opioid receptor levels by activation of protein kinase C in human SH-SY5Y neuroblastoma cells. Anesthesiology 1997; 87: 1127-38.
159. Schultz S, Höllt X. Opioid withdrawal activates MAP kinase in locus coeruleus neurons in morphine-dependent rats in vivo. Eur J Neurosci 1998; 10: 1196-1201.
160. Ortiz J, Harris HW, Guitart X, Terwilliger RZ, Haycock JW, Nestler EJ. Extracellular signal-regulated protein kinase (ERKs) and ERK kinase (MEK) in brain: Regional distribution and regulation by chronic morphine. J Neurosci 1995; 15: 1285-97.
161. 44 mitogen-activated protein kinases following expression of the mouse δ opioid receptor in Rat-1 fibroblasts: Effects of receptor expression levels and comparisons with G-protein activation. Biochem J 1996; 320: 227-35.
162. Fukuda K, Kato S, Morikawa H, Shoda T, Morik functional coupling of the δ, μ, and κ opioid receptors to mitogen-activated protein kinase and arachidonate release in chinese hamster ovary cells. J Neurochem 1996; 67: 1309-16.
163. Gutsein HB, Rubie EA, Mansour A, Akil H, Woodgett GR. Opioid effects on mitogen-activated protein kinase signaling cascades. Anesthesiology 1997; 87: 1118-26.
164. Belcheva MM, Vogel Z, Ignatova E, Avidor-Reiss T, Zippel R, Levy R, Opioid modulation of extracellular signal-regulated protein kinase activity is ras-dependent and involves G βγ subunits. J Neurochem 1998; 70: 635-45.
165. Appleyard SM, Patterson TA, Jin W, Chavkin C. Agonist-induced phosphorylation of the κ-opioid receptor. J Neurochem 1997; 69: 2405-12.
166. Terwilliger RZ, Ortiz J, Guitart X, Nestler EJ. Chronic morphine administration increases β-adrenergic receptor kinase (βARK) levels in the rat locus coeruleus. J Neurochem 1994; 63: 1983-6.
167. Nishino K, Su YF, Wong CS, Watkins WD, Chang KJ. Dissociation of mu opioid tolerance from receptor down-regulation in the rat spinal cord. J Pharm Exp Ther 1990; 253: 67-72.
168. Tao PL, Law PY, Loh HH. Decrease in δ and μ opioid receptor binding capacity in rat brain after chronic etorphine treatment. J Pharm Exp Ther 1987; 240: 809-16.
169. Yabaluri N, Medzihradsky F. Down-regulation of μ-opioid receptor by full but not partial agonists is independent of G protein coupling. Mol Pharmacol 1997; 52: 896-902.
170. Kovoor A, Nappey V, Kieffer BL, Chaukin C. μ and δ opioid receptors are differentially desensitized by the coexpression of β-adrenergic receptor kinase 2 and β-arrestin 2 in Xenopus oocytes. J Biol Chem 1997; 272: 27605-11.
171. 2+-dependent. FEBS Lett 1996; 387: 53-7.
172. Law PJ, Hom DS, Loh HH. Loss of opiate receptor activity in neuroblastoma glioma NG 108-15 hybrid cells after chronic opiate treatment: A multiple step process. Mol Pharmacol 1982; 22: 1-4.
173. Keith DE, Murray SR, Zaki PA, Chu PC, Lissin DV, Kang L, Morphine activates opioid receptors without causing their rapid internalization. et al. J Biol Chem 1996; 271: 19021-4.
174. Befort K, Kieffer BL. Structure-activity relationship in the δ-opioid receptor. Pain Rev 1997; 4: 100-21.
175. Hasbi A, Polastron J, Allouche S, Stanasila L, Masotte D, Jauzac P. Desensitization of the δ-opioid receptor correlates with its phosphorylation in SK-N-BE cells: Involvement of a G protein-coupled receptor kinase. J Neurochem 1998; 70: 2129-38.
176. Pei G, Kieffer BL, Lefkowitz RJ, Freddman NJ. Agonist-dependent phosphorylation of the mouse δ-opioid receptor: Involvement of G protein-coupled receptor kinases but not protein kinase C. Mol Pharmacol 1995; 48: 173-7.
177. Edward DR. Cell signalling and the control of gene transcription. TIPS 1994; 15: 239-44.
178. Quinn JP. Neuronal-specific gene expression. The interaction of both positive and negative transcriptional regulators. Prog Neurobiol 1996; 50: 363-79.
179. Lane-Ladd SB, Pineda J, Boundy VA, Pfeuffer T, Krupinski J, Aghajanian GK, CREB in the locus coeruleus: Biochemical, physiological and behavioral evidence for a role in opiate dependence. J Neurosci 1997; 17: 7890-7901.
180. Guitart X, Thompson MA, Mirante CK, Greenberg M, Nestler EJ. Regulation of cyclic AMP response element-binding protein (CREB) phosphorylation by acute and chronic morphine in the rat locus coeruleus. J Neurochem 1992; 58: 1168-71.
181. Widnell KL, Russel DS, Nestler EJ. Regulation of expression of cAMP response element-binding protein in the locus coeruleus in vivo and in a locus coeruleus-like cell line in vitro. Proc Natl Acad Sci USA 1994; 91: 10947-51.
182. Lazaroff M, Patankar S, Okyoon S, Chikaraishi D. The cyclic AMP response element directs tyrosine hydroxylase expression in cathecholaminergic central and peripheral nervous system cell lines from transgenic mice. J Biol Chem 1995; 270: 21579-89.
183. Holmes PV, DeBartolomeis A, Koprivica V, Crawley JN. Lack of effect of chronic morphine treatment and naloxone-precipited withdrawal on tyrosine hydroxylase, galanin, and neuropeptide Y mRNA levels in the rat locus coeruleus. Synapse 1995; 19: 197-205.
184. Hayward MD, Duman RS, Nestler EJ. Induction of the c-fos proto-oncogene during opiate withdrawal in the locus coeruleus and other regions of the brain. Brain Res 1990; 525: 256-66.
185. Stornetta RL, Norton FE, Guyenet PG. Autonomie areas of rat brain exhibit increased fos-like immunoreactivity during opiate withdrawal in rats. Brain Res 1993; 624: 19-28.
186. Buzas B, Rosenberger J, Cox BM. Mu and delta opioid receptor expression after chronic treatment with opioid agonist. Neuro Report 1996; 7: 1505-8.
187. Brodsky M, Elliot K, Hynansky A, Minami M, Inturrisi C. NMDA receptor and proenkephalin gene expression are modulated by chronic morphine administered alone or in combination with NMDA antagonist [abstract]. Soc Neurosci 1993; 19: 1352.
188. Romualdi P, Lesa G, Ferri S. Chronic opiate agonists down-regulate prodynorphin gene expression in rat brain. Brain Res 1991; 563: 132-6.